Teleflex’s Acquisition of BIOTRONIK’s Vascular Business and Intent to Split into Two Entities

The medtech industry witnessed another significant shift in February 2025 as Teleflex made two major announcements that have the potential to reshape its future. On February 27th, Teleflex revealed plans to divide into two separate publicly traded entities, each focusing on different aspects of the business. In addition, the company announced that it would acquire BIOTRONIK’s vascular intervention business for approximately $791 million. This strategic move underscores Teleflex’s commitment to expanding its footprint in the vascular market.

As Teleflex transitions into this new phase, the focus shifts to understanding what this acquisition means for the company’s growth and the broader spinal cord stimulation market. The decision to integrate BIOTRONIK’s vascular intervention portfolio further strengthens Teleflex’s presence in the vascular access and interventional fields. But what does this deal signal about the company’s future and the landscape of the vascular market?

In this blog, we’ll dive into the details of Teleflex’s acquisition, examine the strategic reasons behind it, and explore the potential market dynamics it will influence.

The Business Segments Behind Teleflex’s Acquisition

Teleflex’s decision to split its operations into two distinct entities is designed to allow each unit to focus on its core markets more effectively. The new company, dubbed “NewCo,” will center on urology, acute care, and OEM businesses, while the other, “RemainCo,” will focus on vascular access, interventional, and surgical businesses. This division is expected to increase management focus and drive growth in their respective sectors.

Teleflex’s vascular business, a key segment within RemainCo, generated an estimated $1.32 billion in revenue in 2024 from its vascular access devices and interventional products. With the addition of BIOTRONIK’s vascular intervention business, Teleflex is well-positioned to capitalize on the expanding vascular market — particularly in the interventional space, which saw a 14.6% year-over-year growth in 2024.

This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/teleflexs-acquisition-of-biotroniks-vascular-business-and-intent-to-split-into-two-entities 

Comments

Post a Comment

Popular posts from this blog

The Weekly Recap 6/13/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $63M in new funds, receive FDA 510(k) clearances, announce an acquisition, and much more as we wind down   LSI Asia  ’25 in Singapore and gear up for  LSI Europe  ’25 in London (September 7–11). Accelus Received FDA 510(k) clearance for the FlareHawk Interbody Fusion System to be safely subjected to MRI scanning in certain conditions. The clearance supports Accelus’s commitment to safe, high-performance spinal solutions and expands imaging options for patients with FlareHawk implants. Aortyx Raised $16M to advance its bioresorbable aortic patch toward first-in-human trials. The funding supports continued development of Aortyx’s minimally invasive, tissue-regenerating solution for aortic dissection and positions the company for clinical entry within two years. Atraverse Medical Closed $29.4M in follow-on financing to scale U.S. commercialization of HOTW...
Read more

Medtech in 2025: Key Insights from Q1 Earnings

  As we venture into Q2 of 2025, the medtech industry continues to navigate challenges while remaining on a positive growth trajectory. The early earnings reports from major medtech companies provide valuable insights into how the sector is performing and where it is heading. Despite the pressures of ongoing macroeconomic uncertainty, the first quarter of 2025 shows a sector that’s resilient, with many companies reporting strong growth across their key divisions. For more information visit here:  https://www.slideshare.net/slideshow/medtech-in-2025-key-insights-from-q1-earnings/279045324
Read more

Q1 2025 Medical Device Investment Roundup: A Record-Breaking Start to a Year of Reckoning

Big deals, even bigger questions. Jonathan Norris of HSBC Innovation Banking explains why 2025 is already one for the books. Venture investment across the medical device sector kicked off 2025 with a bang, posting $2.6 billion in first-quarter funding across 132 deals — the highest quarterly dollar mark in three years. According to  Jonathan Norris , Managing Director at  HSBC Innovation Banking , who writes comprehensive reports on the venture healthcare ecosystem, this surge marks a 20% rise in both capital and deal count compared to the 2024 average. “Not only did we have more dollars, but there were more deals, which is really good to see,” Norris says, in a recent interview with  The Lens . “I think the quick and easy takeaway is that more companies were getting funded in Q1, and a good percentage of the bigger deals in the quarter were PMA pivotal trial rounds. It looks like positive momentum for the sector to see a big quarter. That’s our 35,000-foot view.” But ben...
Read more